3-(乙氧基甲酰基)吡啶-5-硼酸频哪醇酯 | 916326-10-8

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 3-(乙氧基甲酰基)吡啶-5-硼酸频哪醇酯
• 中文别名: 3-乙氧羰基吡啶-5-硼酸频哪醇酯；5-(4,4,5,5-四甲基-[1,3,2]二氧硼烷)烟酸乙酯
• 英文名称: ethyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)nicotinate
• 英文别名: ethyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine-3-carboxylate；5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)nicotinic acid ethyl ester；5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)nicotinic acid ethyl ester；3-(ethoxycarbonyl)-pyridine-5-boronic acid pinacol ester；3-(ethoxycarbonyl)pyridine-5-boronic acid pinacol ester；5-ethoxycarbonylpyridine-3-boronic acid pinacol ester
• CAS: 916326-10-8
• 化学式: C₁₄H₂₀BNO₄
• mdl: MFCD04117940
• 分子量: 277.128
• InChiKey: ZKGQTSJZFBTEOB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.08
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.571
• 拓扑面积：
  57.6
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  2-8°C，惰性气体

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-(Ethoxycarbonyl)pyridine-5-boronic acid pinacol ester
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-(Ethoxycarbonyl)pyridine-5-boronic acid pinacol ester
CAS number: 916326-10-8

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C14H20BNO4
Molecular weight: 277.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-(乙氧基甲酰基)吡啶-5-硼酸频哪醇酯 在 1,1'-bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane complex 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 水 、 甲苯 为溶剂， 反应 11.5h， 生成 1,3-二氢-8-[5-(1-羟基-1-甲基乙基)-3-吡啶基]-1-[(2S)-2-甲氧基丙基]-3-甲基-2H-咪唑并[4,5-c]喹啉-2-酮
  参考文献：
  名称：

  PI3 KINASE/mTOR DUAL INHIBITOR

  摘要：

  本发明提供了一种imidazo[4,5-c]quinolin-2-one化合物，或其药用可接受的盐，可以抑制PI3K和mTOR，因此在癌症治疗中具有用处。

  公开号：

  US20120184577A1
• 作为产物：
  描述：

  烟酸乙酯 、 联硼酸频那醇酯 在 (1,5-cyclooctadiene)(methoxy)iridium(I) dimer 、 4,4'-二叔丁基-2,2'-二吡啶 作用下， 以 四氢呋喃 为溶剂， 反应 18.0h， 生成 3-(乙氧基甲酰基)吡啶-5-硼酸频哪醇酯
  参考文献：
  名称：

  芳烃的区域选择性转化为N-芳基-1,2,3-三唑用C ？H硼化

  摘要：

  的单釜协议用于合成Ñ -芳基的1,2,3-三唑从芳烃通过铱催化的Ç  ħ硼化/铜催化的叠氮化/击序列进行说明。发现1mol％的Cu（OTf）2有效地催化了叠氮化和点击反应。1,2,3-三唑部分在化学上重要的未活化分子的后期化学选择性安装证明了该方法的适用性。

  DOI：

  10.1002/chem.201403021

文献信息

• Fragment-to-Hit-to-Lead Discovery of a Novel Pyridylurea Scaffold of ATP Competitive Dual Targeting Type II Topoisomerase Inhibiting Antibacterial Agents
  作者：Gregory S. Basarab、John I. Manchester、Shanta Bist、P. Ann Boriack-Sjodin、Brian Dangel、Ruth Illingworth、Brian A. Sherer、Shubha Sriram、Maria Uria-Nickelsen、Ann E. Eakin

  DOI：10.1021/jm401208b

  日期：2013.11.14

  The discovery and optimization of a new class of bacterial topoisomerase (DNA gyrase and topoisomerase IV) inhibitors binding in the ATP domain are described. A fragment molecule, 1-ethyl-3-(2-pyridyl)urea, provided sufficiently potent enzyme inhibition (32 μM) to prompt further analogue work. Acids and acid isosteres were incorporated at the 5-pyridyl position of this fragment, bridging to a key asparagine

  描述和发现了一种新型的结合在ATP域中的细菌拓扑异构酶（DNA促旋酶和拓扑异构酶IV）抑制剂。片段分子1-乙基-3-（2-吡啶基）脲提供了足够强的酶抑制作用（32μM），可促进进一步的类似工作。在该片段的5-吡啶基位置掺入了酸和酸等排体，桥接至关键的天冬酰胺残基，改善了酶抑制作用，并产生了可测量的抗菌活性。由于有利的亲脂性相互作用，在4-吡啶基位置的CF 3-噻唑取代基改善了抑制能力。与革兰氏阳性病原体金黄色葡萄球菌和肺炎链球菌相比，具有良好的抗菌活性和革兰氏阴性病原流感嗜血杆菌和卡他莫拉菌。前体代谢物的掺入和突变分析研究支持双分子拓扑异构酶抑制作用的作用方式，DNA合成的阻断。化合物35在小鼠金黄色葡萄球菌疾病模型中是有效的，其中证明了菌落形成单位相对于对照减少了4.5个对数。
• Use of Inhibitors of the Activity or Function of PI3K
  申请人：NOVARTIS AG

  公开号：US20150342951A1

  公开（公告）日：2015-12-03

  The invention relates to new uses of PI3K inhibitors, wherein said inhibitors have an inhibitory action on the PI3K isoform delta for the treatment of immunopathology in a subject suffering from a disease or disorder selected from malaria, leishmaniasis, trypanosomiasis, toxoplasmosis and/or neurocysticercosis, via functional inhibition of TLR9 of the infected subject.

  该发明涉及PI3K抑制剂的新用途，其中所述抑制剂对PI3K同工酶δ具有抑制作用，用于治疗患有疟疾、利什曼病、锥虫病、弓形虫病和/或神经囊虫病等疾病或紊乱的受试者的免疫病理学，通过对感染受试者的TLR9的功能抑制。
• [EN] SUBSTITUTED 3-PHENYLQUINAZOLIN-4(3H)-ONES AND USES THEREOF<br/>[FR] 3-PHÉNYLQUINAZOLIN-4(3H)-ONES SUBSTITUÉS ET LEURS UTILISATIONS
  申请人：BAYER AG

  公开号：WO2019063704A1

  公开（公告）日：2019-04-04

  The present invention covers substituted 3-Phenylquinazolin-4(3H)-one compounds of general formula (I) as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of various inflammatory and fibrotic diseases of the respiratory tract and of the lungs as well as lung cancer, as a sole agent or in combination with other active ingredients.

  本发明涵盖了通式(I)所述和定义的取代3-苯基喹唑啉-4(3H)-酮化合物，制备该化合物的方法，用于制备该化合物的有用中间体化合物，包含该化合物的药物组合物和组合物，以及利用该化合物制造用于治疗或预防疾病的药物组合物的用途，特别是用于治疗和/或预防呼吸道和肺部的各种炎症性和纤维化疾病以及肺癌，作为唯一药剂或与其他活性成分组合使用。
• CHEMICAL COMPOUNDS
  申请人：Basarab Gregory Steven

  公开号：US20080132546A1

  公开（公告）日：2008-06-05

  Compounds of formula (I) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.

  描述了化合物的公式（I）及其药用可接受的盐。还描述了它们的制备过程，含有它们的药物组合物，它们作为药物的用途以及它们在治疗细菌感染中的用途。
• Pyrrolopyrimidines and Pyrrolopyridines
  申请人：Leblanc Catherine

  公开号：US20090181941A1

  公开（公告）日：2009-07-16

  Compounds of formula I in free or salt or solvate form, wherein X, T 1 , T 3 and T 4 have the meanings as indicated in the specification, are useful for treating diseases mediated by the ALK-5 and/or ALK-4 receptor. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

  公式I的化合物，无论是游离形式、盐形式还是溶剂化物形式，其中X、T1、T3和T4的含义如说明书中所指，可用于治疗由ALK-5和/或ALK-4受体介导的疾病。还描述了包含这些化合物的药物组合物以及制备这些化合物的方法。